Clinical TrialJul 2, 2026, 08:33 AM
Trinity Biotech CGM+ Validates False Low Glucose Detection
AI Summary
Trinity Biotech announced positive clinical study results for its next-generation CGM+ wearable biosensor platform. The analysis of over 5,000 hours of clinical wear data validated the device's ability to distinguish nocturnal compression-related false low glucose events from true blood glucose lows. This capability addresses a common limitation of conventional CGM systems, improving user experience by reducing false alarms and providing richer data for automated insulin delivery systems. The company believes this strengthens the differentiation and commercial opportunity for its CGM+ solution, which is in the latter stages of development.
Key Highlights
- CGM+ validated false low glucose detection using 5,000 hours of clinical data.
- Addresses common limitation of conventional continuous glucose monitoring (CGM) systems.
- Reinforces CGM+ differentiation in the $15 billion global CGM market.
- Compression lows occur every 5-6 days in conventional CGMs.
- CGM+ combines glucose with heart activity, temperature, and physical activity.
- CGM+ is in latter stages of development, moving to pivotal trial and regulatory submission.
- Clinical wear data collected from insulin-dependent people with diabetes.
Price Impact
More from TRIB